VICARIOUS SURGICAL INC (RBOT)

OTCHealth CareMedical - DevicesSnapshot 2026-10-23

$0.03-70.78%

Close 2026-10-23 · 1-day change

VICARIOUS SURGICAL INC (RBOT) Outlook: What's Priced In | QuarterlyIQ

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge VICARIOUS SURGICAL INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-31
Revenue	—	0
EPS	—	-0.61
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-4.07
Annual ending 2027-12-31
Revenue	—	18M
EPS	—

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain leadership stability after CFO resignation	Leadership is working to stabilize after recent executive changes.	Under Pressure	CFO position remains vacant beyond 2026-Q3	CFO vacant since 2026-06-24; no successor named CFO Sarah Romano resigned without a successor on 2026-06-24. The company completed an assignment for the benefit of creditors on 2026-07-21. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 1
2026-07-25	Unavailable	Unavailable	1 / 1
2026-07-26	Unavailable	Unavailable	1 / 1
2026-07-27	Unavailable	Unavailable	1 / 1
2026-07-28	Unavailable	Unavailable	1 / 1
2026-07-29	Unavailable	Unavailable

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain leadership stability after CFO resignationPublished status: Under Pressure
Reduce full-year cash burn to $19 million in 2026Direct metric needs a verified mapping
Reduce operating losses to $9.3 million by 2025-Q4Published status: Broken

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

9.2%Typical daily move · historical

Downside history

-100.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

VICARIOUS SURGICAL INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

RBOT is a high-risk, loss-making healthcare business with a sector tailwind, not yet a proven durable compounder. Its long-term thesis is intact, but evidence is limited and confidence is low.

What's priced into VICARIOUS SURGICAL INC

The evidence snapshot does not provide a valuation or clear expectations already reflected by the market, so whether RBOT is cheap, fair, or expensive versus peers cannot be assessed. The company remains loss-making, which makes valuation evidence especially thin.

What the fundamentals likely do

Near term, management is working to reduce 2026 cash burn to $19 million, after lowering its guidance from $50 million to $35 million and then $19 million; operating and net losses also improved through 2025. These priorities remain under watch, and CEO and CFO departures add execution risk; a guidance cut would be a meaningful negative.

What VICARIOUS SURGICAL INC hinges on

The multi-year thesis hinges on whether management delivers lower cash burn and steadier leadership while improving financial stability. In the near term, weaker jobs data could weigh on cyclical healthcare names, while continued earnings strength and higher guidance from sector peers could support the sector backdrop.

Bottom line

Over the next 1 to 3 years, the thesis remains intact but fragile: progress on cash burn and losses must continue, while leadership changes and high risk remain important concerns. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

VICARIOUS SURGICAL INC (RBOT)

What could strengthen or challenge VICARIOUS SURGICAL INC’s outlook?

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Next proof point

Historical risk context

VICARIOUS SURGICAL INC outlook in detail

What kind of bet this is

What's priced into VICARIOUS SURGICAL INC

What the fundamentals likely do

What VICARIOUS SURGICAL INC hinges on

Bottom line

Analyst view

Price-target changes

Bottom line